The real cost of proving the safety of a gene-edited clone

As we recognize the increasingly important role of gene-edited induced pluripotent stem cells (iPSCs) in cell and gene therapies, it is easy to overlook the enormous amount of work and cost required to take a single candidate to the starting line of the regulatory pipeline. But it doesn’t have to be this complex; most of the cost comes from making results regulator-ready and the number of hands they have to pass through.

The tip of the iceberg represents only a tiny fraction of the full sequencing requirements placed on gene-edited iPSCs, especially to those observing the spectacle from the outside. However, the quality assurance (QA) professionals in the business see the full picture. They recognize these complexities all too well. They know the sponsor requires reliable approaches to confirm edited clones that don’t carry harmful off-target changes. They know the steps towards IND filings are slow, expensive, multi-step processes.

A lot happens between the sponsor, who owns the therapy program, and the QA expert who has to make sense of the data. Sure, the contract development and manufacturing organization (CDMO) takes care of clone selection, banking, and GMP production, and it can take on some of the sequencing. But the specialized sequencing tasks, such as off-target analyses, may outsource to specialized CROs with dedicated sequencing expertise.

From there, the results flow back to the CDMO, then further to a QA professional who interprets the results and hands the outcome to regulatory affairs to defend before regulators, such as FDA and EMA. Every extra link in that chain increases the risk of assessments getting lost in translation and adds expenses and time. That’s exactly why an accurate, yet simple procedure like TIDE becomes invaluable in the pipeline.

The cost of outsourcing

While we might think the majority of the sequencing costs in cell therapy arise from reagents, the true cost lies in ensuring the program survives regulatory reviews. Although we can get away with cost-effective research-grade options, data intended for IND involves most of the expenses.

Take gene editing for an iPSC program, for instance. A single gene-edited clone requires several rounds of sequencing, including on-target amplicon-seq for zygosity and indel spectrum, and then long-read or LAM-PCR to map insertions. These sequencing analyses are followed by off-target nomination, combining in silico prediction with empirical methods, such as GUIDE-, CIRCLE-, or DISCOVER-seq, and any identified site needs verification. Once we add translocation and chromosomal-integrity analyses, it’s clear the genome has been examined from multiple angles before we’ve even reached the final product.

It’s also becoming more challenging to convince the regulatory agencies. FDA’s April 2026 draft guidance recommends combining targeted amplicon methods with unbiased genome-wide approaches for off-target assessment. Its CBER unit also expects nomination in relevant human cell types from multiple replicates and verification with adequately sensitive methods.

Most importantly, the FDA requires the drug product’s targeted deep-sequencing step to come from a qualified assay with documented performance. This one-time validation fee, in the low-to-mid six figures, gets passed on to sponsors. The per-sample costs after that sit at 2–4× the research-grade rate. Due to the validation being a one-time cost, smaller companies and early-stage programs running fewer samples pay relatively more than larger ones, considering that the same fixed cost gets divided across less volume. Add to that, sequencing costs 8–15% of the CMC (chemistry, manufacturing, and controls) budget for multiplex-edited iPSC programs. And that’s not even counting the 10–25% profit margin CDMOs charge once they pass the specialized sequencing assignment to CROs.

The time it takes

The cost above is disproportionately high on the most critical path: off-target identification. A regulated off-target package takes 3–6 months end-to-end, including nomination, panel design, verification of the final clone, and reporting. That’s excluding the time it takes to establish the actual candidate clones and any delays in the procedure. When a package slips, which it often does, the issue spreads to other stakeholders in the chain. Sponsors start questioning whether to keep the CDMO, and QA still has to explain the delay to regulatory affairs.

This relatively slow procedure has incentivized CDMOs to create and sell pre-made lines with characterized edits and off-target data. For example, a sponsor can purchase a so-called “chassis” iPSC line with an edited HLA to reduce immune rejection, which the sponsor can license or buy. Sponsors use these lines as starting points to build their own additional edits.

The TIDE solution

Here’s the most natural question: why then can’t sponsors simply buy chassis lines to circumvent the time-consuming gene characterization involved in the process, even if it means higher costs upfront?

Although the option has real benefits for sponsors, chassis lines only help with the edits associated with pre-established clones. In other words, the moment a company needs a different target, indel profile, or knock-in, or wishes not to be locked into external platforms with licensing, IP, or customization constraints, the chassis becomes a limitation rather than a solution. At that moment, sponsors are back to the sequencing pipeline.

But it’s also at those moments that a regulatory-compliant approach can help QA professionals move from point A (candidate clone) toward point B (IND) more quickly and seamlessly.

As we’ve previously described, Vertex Therapeutics reached this same conclusion when developing CASGEVY, the first FDA-approved CRISPR therapy. For on-target validations, a single Sanger-based TIDE reaction delivers results about 99% as accurate as NGS, in a fraction of the time. TIDE’s 21 CFR Part 11-compliant GxP software gives QA teams a defensible, tested way to close the on-target piece of the pipeline. For a more complete chain, TIDE Genetics also builds custom workflows for off-target detection.